

Interacciones farmacológicas con inhibidores de la tirosina quinasa imatinib, dasatinib y nilotinib

Tabla en el artículo siguiente: Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. *Blood* 2010.

ARTICULO COMPLETO EN INGLES EN LA SECCIÓN DE interacciones con otros medicamentos DE ESTA WEB CON EL TITULO

Blood-2011-Haouala-e75-87 documento PDF

Legenda:

La Tabla (en 17 partes) resume las posibles interacciones medicamentosas observadas entre *TKI* y medicamentos comúnmente prescritos concomitantemente o agentes clásicos interactuantes (líneas) ordenados según la clasificación ATC. Las flechas **↑ y ↓ indican un aumento o disminución de la concentración del fármaco respectivamente**. En el **texto en negrita se describen las interacciones en la literatura** (número de referencia), **mientras que los caracteres estándar representan posibles interacciones predichas a partir de consideraciones teóricas** (pero aún no publicada en la literatura). **La ausencia de interacción** es la consecuencia de un estudio clínico (número de referencia), y **una caja sombreada en gris significa que no hay interacción está bien informado o teóricamente esperado**.

Descargo de responsabilidad

Esta tabla resume las posibles interacciones farmacológicas entre algunos medicamentos comúnmente prescritos (**líneas**) y tres inhibidores de tirosina quinasa (**columnas**). Cada celda indica el tipo de interacción esperada cuando el fármaco se toma junto con el inhibidor de tirosina quinasa correspondiente. Sin embargo, los datos presentados son indicativos y no sustituyen el juicio clínico necesario cuando para el tratamiento de pacientes con múltiples fármacos. No se espera que todas las interacciones que tienen importancia clínica y / o que implique modificación en su dosis.

Sistema digestivo y metabolismo

		Imatinib	Dasatinib	Nilotinib
PPI	Omeprazole	<ul style="list-style-type: none"> Inhibition of Pgp by omeprazole : ↑ imatinib exposure 	<ul style="list-style-type: none"> ↓ dasatinib absorption 	
	Esomeprazole	<ul style="list-style-type: none"> Inhibition of Pgp by esomeprazole : ↑ imatinib exposure 	<ul style="list-style-type: none"> ↓ dasatinib absorption 	
	Pantoprazole	<ul style="list-style-type: none"> Inhibition of Pgp by pantoprazole: ↑ imatinib exposure 	<ul style="list-style-type: none"> ↓ dasatinib absorption 	
H2-antagonists	Cimetidine	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and Pgp by cimetidine : ↑ imatinib exposure Inhibition of hOCT1 by cimetidine : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> ↓ dasatinib absorption 	Inhibition of CYP 3A4 by cimetidine : ↑ nilotinib exposure
	Ranitidine	<ul style="list-style-type: none"> Inhibition of Pgp by ranitidine : ↑ imatinib exposure Inhibition of hOCT1 by ranitidine : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> ↓ dasatinib absorption 	
Antiemetics	Metoclopramide		<ul style="list-style-type: none"> ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> ↑ QT interval (additive effect) → monitor ECG
Antidiabetic drugs	Insulin			
	Metformin	<ul style="list-style-type: none"> Inhibition of hOCT1 by metformin : ↓ imatinib intracellular exposure 		
	Glibenclamide	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by imatinib: ↑ glibenclamide exposure Inhibition of Pgp by glibenclamide : ↑ imatinib exposure 	Inhibition of CYP 3A4 by dasatinib: ↑ glibenclamide exposure Inhibition of Pgp by glibenclamide : ↑ dasatinib exposure	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by nilotinib: ↑ glibenclamide exposure
	Acarbose			
	Rosiglitazone	<ul style="list-style-type: none"> Inhibition of CYP 2C9 by imatinib: ↑ rosiglitazone exposure 		<ul style="list-style-type: none"> Inhibition of CYP 2C9 by nilotinib: ↑ rosiglitazone exposure
	Pioglitazone	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by imatinib: ↑ pioglitazone exposure 	Inhibition of CYP 3A4 by dasatinib: ↑ pioglitazone exposure	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by nilotinib: ↑ pioglitazone exposure
	Nateglinide	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by imatinib: ↑ nateglinide exposure 	Inhibition of CYP 3A4 by dasatinib: ↑ nateglinide exposure	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C9 by nilotinib: ↑ nateglinide exposure
Repaglinide	<ul style="list-style-type: none"> Inhibition of CYP 3A4 by imatinib: ↑ pioglitazone exposure 	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C8 by dasatinib: ↑ pioglitazone exposure 	<ul style="list-style-type: none"> Inhibition of CYP 3A4 and 2C8 by nilotinib: ↑ pioglitazone exposure 	

La sangre y los órganos

		Imatinib	Dasatinib	Nilotinib
Antiplatelet drug ^a	Clopidogrel	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2C19 by imatinib: <ul style="list-style-type: none"> ↑ clopidogrel exposure ↓ clopidogrel bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: <ul style="list-style-type: none"> ↑ clopidogrel exposure ↓ clopidogrel bioactivation • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: <ul style="list-style-type: none"> ↑ clopidogrel exposure ↓ clopidogrel bioactivation
	Anticoagulants ^a	Acenocoumarol	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: <ul style="list-style-type: none"> ↑ anticoagulation → monitor PT/INR 	<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding
Phenprocoumon		<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: <ul style="list-style-type: none"> ↑ anticoagulation → monitor PT/INR 	<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: <ul style="list-style-type: none"> ↑ anticoagulation → monitor PT/INR
Warfarin		<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: <ul style="list-style-type: none"> ↑ anticoagulation → monitor PT/INR 	<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: <ul style="list-style-type: none"> ↑ anticoagulation → monitor PT/INR
Heparin		<ul style="list-style-type: none"> • Inhibition of Pgp by heparin: <ul style="list-style-type: none"> ↑ imatinib exposure 	<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding • Inhibition of Pgp by heparin: <ul style="list-style-type: none"> ↑ dasatinib exposure 	
Enoxaparin			<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	
Nadroparin			<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	
Dalteparin			<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: <ul style="list-style-type: none"> ↑ risk of bleeding 	

sistema cardiovascular

		Imatinib	Dasatinib	Nilotinib
Calcium channel blockers	Verapamil	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ verapamil exposure • Inhibition of CYP 3A4 and Pgp by verapamil: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ verapamil exposure • Inhibition of CYP 3A4 and Pgp by verapamil: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ verapamil exposure • Inhibition of CYP 3A4 by verapamil: ↑ nilotinib exposure
	Diltiazem	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ diltiazem exposure • Inhibition of CYP 3A4 and Pgp by diltiazem: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ diltiazem exposure • Inhibition of CYP 3A4 and Pgp by diltiazem: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ diltiazem exposure • Inhibition of CYP 3A4 by diltiazem: ↑ nilotinib exposure
	Nifedipine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ nifedipine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ nifedipine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP3A4 by nilotinib: ↑ nifedipine exposure
	Amlodipine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ amlodipine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ amlodipine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ amlodipine exposure
NO precursors	Molsidomine			
	Isosorbid mononitrate (ISMN)	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ ISMN exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ ISMN exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ ISMN exposure
	Isosorbid dinitrate (ISDN)	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ ISDN exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ ISDN exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ ISMN exposure
	Nitroglycerine			
HMG-CoA reductase inhibitors	Simvastatin	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ simvastatin exposure • Inhibition of Pgp by simvastatin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ simvastatin exposure • Inhibition of Pgp by simvastatin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ simvastatin exposure
	Pravastatin			
	Atorvastatin	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ atorvastatin exposure • Inhibition of Pgp by atorvastatin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ atorvastatin exposure • Inhibition of Pgp by atorvastatin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ atorvastatin exposure
	Rosuvastatin			
Antiarrhythmic drugs	Amiodarone	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ amiodarone exposure • Inhibition of CYP3A4 and Pgp by amiodarone: ↑ imatinib exposure Inhibition of hOCT1 by amiodarone: ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ amiodarone exposure • Inhibition of CYP 3A4 and Pgp by amiodarone: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp and CYP 3A4 by nilotinib: ↑ amiodarone exposure • Inhibition of CYP 3A4 by amiodarone: ↑ nilotinib exposure • ↑ QT interval (additive effect) => monitor ECG
	Quinidine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ quinidine exposure • Inhibition of Pgp by quinidine: ↑ imatinib exposure • Inhibition of hOCT1 by quinidine: ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ quinidine exposure • Inhibition of Pgp by quinidine: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ quinidine exposure

		Imatinib	Dasatinib	Nilotinib
Diuretics	Furosemide	<ul style="list-style-type: none"> • Absence of interaction 		
	Torsemide	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: ↑ torsemide exposure 		<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: ↑ torsemide exposure
	Hydrochlorothiazide			
	Spironolactone	<ul style="list-style-type: none"> • Inhibition of Pgp by spironolactone: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by spironolactone: ↑ dasatinib exposure 	
Beta blockers	Metoprolol	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ metoprolol exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by metoprolol: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ metoprolol exposure
	Bisoprolol	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ bisoprolol exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ bisoprolol exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ bisoprolol exposure
	Carvedilol	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 2D6 by imatinib: ↑ carvedilol exposure • Inhibition of Pgp by carvedilol: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by carvedilol: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 2D6 by nilotinib: ↑ carvedilol exposure
	Atenolol	<ul style="list-style-type: none"> • Absence of interaction 		
ACE inhibitors	Captopril	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ captopril exposure • Inhibition of Pgp by captopril: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by captopril: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ captopril exposure
	Enalapril	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ enalapril exposure • Inhibition of Pgp by enalapril: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by enalapril: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ enalapril exposure
	Ramipril			
	Lisinopril	<ul style="list-style-type: none"> • Inhibition of Pgp by imatinib: ↑ lisinopril exposure • Inhibition of Pgp by lisinopril: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by lisinopril: ↑ dasatinib exposure 	
AT II receptor blockers	Losartan	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 3A4 by imatinib: losartan exposure and ↓ losartan bioactivation • Inhibition of Pgp by losartan: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ losartan exposure • Inhibition of Pgp by losartan: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 3A4 by nilotinib: ↑ losartan exposure and ↓ losartan bioactivation
	Candesartan			
Cardiac glycosides	Digoxin	<ul style="list-style-type: none"> • ↓ digoxin absorption (unknown mechanism) 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG • Inhibition of Pgp by nilotinib: ↑ digoxin exposure

preparaciones hormonales

		Imatinib	Dasatinib	Nilotinib
Corticosteroids	Prednisone			
	Dexamethasone	<ul style="list-style-type: none"> • Induction of CYP 3A4 by dexamethasone : ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by dexamethasone : ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by dexamethasone : ↓ nilotinib exposure
	Betamethasone			
Thyroid therapy	Levothyroxine	<ul style="list-style-type: none"> • Induction of UGTs by imatinib : ↓ levothyroxine • Inhibition of CYP 3A4 by levothyroxine: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by levothyroxine: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by levothyroxine: ↑ nilotinib exposure
	Carbimazole			
Antineoplastic agents	Cyclophosphamide	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 and 3A4 by imatinib: ↑ cyclophosphamide exposure ↓ cyclophosphamide bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ cyclophosphamide exposure ↓ cyclophosphamide bioactivation 	<ul style="list-style-type: none"> • Induction of CYP 2B6 by nilotinib: ↓ cyclophosphamide exposure ↑ cyclophosphamide bioactivation
Antiestrogen agent	Tamoxifen	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 and 3A4 by imatinib: ↑ tamoxifen exposure ↓ tamoxifen bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ tamoxifen exposure ↓ tamoxifen bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 and 3A4 by nilotinib: ↑ tamoxifen exposure ↓ tamoxifen bioactivation

Antiinfecciones

		Imatinib	Dasatinib	Nilotinib
Amoxicillin				
Penicillins	Flucloxacillin			
	Céfuroxime			
Cephalosporins	Cefpodoxime			
	Ceftriaxone			
	Clarithromycin			
Macrolides	Azithromycin	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by clarithromycin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by clarithromycin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by clarithromycin: ↑ nilotinib exposure
	Erythromycin	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by erythromycin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by erythromycin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by erythromycin: ↑ nilotinib exposure
Tertracyclines	Doxycyclin			
Quinolones	Ciprofloxacin	<ul style="list-style-type: none"> • Inhibition of Pgp by ciprofloxacin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG • Inhibition of Pgp by ciprofloxacin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
	Levofloxacin	<ul style="list-style-type: none"> • Inhibition of Pgp by levofloxacin: ↑ imatinib exposure • Inhibition of hOCT1 by levofloxacin: ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG • Inhibition of Pgp by levofloxacin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
	Norfloxacín		<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
Sulfonamides	Co-trimoxazole	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: ↑ co-trimoxazole 		<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: ↑ co-trimoxazole

		Imatinib	Dasatinib	Nilotinib
Azoles	Itraconazole	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by itraconazole: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by itraconazole: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by itraconazole: ↑ nilotinib exposure
	Fluconazole	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by fluconazole: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by fluconazole: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by fluconazole: ↑ nilotinib exposure • ↑ QT interval (additive effect) → monitor ECG
	Voriconazole	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by voriconazole: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by voriconazole: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by voriconazole: ↑ nilotinib exposure • ↑ QT interval (additive effect) → monitor ECG
	Ketoconazole	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by ketoconazole: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by ketoconazole: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by ketoconazole: ↑ nilotinib exposure • ↑ QT interval (additive effect) → monitor ECG
Allylamine	Terbinafine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2C9 by imatinib: ↑ terbinafine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ terbinafine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2C9 by nilotinib: ↑ terbinafine exposure
Nitroimidazole	Metronidazole			
Antiviral/Nucleoside analog	Aciclovir	<ul style="list-style-type: none"> • Absence of interaction 		
	Valaciclovir	<ul style="list-style-type: none"> • Absence of interaction 		
	Ganciclovir	<ul style="list-style-type: none"> • Inhibition of hOCT1 by ganciclovir : ↓ imatinib intracellular exposure 		
	Valganciclovir	<ul style="list-style-type: none"> • Inhibition of hOCT1 by ganciclovir : ↓ imatinib intracellular exposure 		
Antimycobacterials	Rifampicine	<ul style="list-style-type: none"> • Induction of CYP 3A4 by rifampicine: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by rifampicine: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by rifampicine: ↓ nilotinib exposure
	Isoniazide			
	Ethambutol			

		Imatinib	Dasatinib	Nilotinib
Protease inhibitors	Ritonavir		<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by ritonavir: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by ritonavir: ↑ nilotinib exposure • ↑ QT interval (additive effect) → monitor ECG
	Saquinavir	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ saquinavir exposure • Inhibition of hOCT1 by saquinavir : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ saquinavir exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ saquinavir exposure
	Darunavir	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by darunavir: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by darunavir: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by darunavir: ↑ nilotinib exposure
	Atazanavir	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ atazanavir exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ atazanavir exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ atazanavir exposure
	Tipranavir	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ tipranavir exposure • Inhibition of CYP 3A4 by tipranavir: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ tipranavir exposure • Inhibition of CYP 3A4 by tipranavir: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ tipranavir exposure • Inhibition of CYP 3A4 by tipranavir: ↑ nilotinib exposure
	Indinavir	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ indinavir exposure • Inhibition of hOCT1 by indinavir : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ indinavir exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ indinavir exposure
Nucleoside and nucleotide reverse transcriptase inhibitors	Lamivudine	<ul style="list-style-type: none"> • Inhibition of hOCT1 by lamivudine : ↓ imatinib intracellular exposure 		
	Emtricitabine			
	Zidovudine			
Non-nucleoside reverse transcriptase inhibitors	Efavirenz	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ efavirenz exposure • Induction of CYP 3A4 by efavirenz: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ efavirenz exposure • Induction of CYP 3A4 by efavirenz: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ efavirenz exposure • Induction of CYP 3A4 by efavirenz: ↓ nilotinib exposure
	Nevirapine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ nevirapine exposure • Induction of CYP 3A4 by nevirapine: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ nevirapine exposure • Induction of CYP 3A4 by nevirapine: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ nevirapine exposure • Induction of CYP 3A4 by nevirapine: ↓ nilotinib exposure
	Etravirine	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 3A4 by imatinib: ↑ etravirine exposure • Induction of CYP 3A4 by etravirine: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ etravirine exposure • Induction of CYP 3A4 by etravirine: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 3A4 by nilotinib: ↑ etravirine exposure • Induction of CYP 3A4 by etravirine: ↓ nilotinib exposure

		Imatinib	Dasatinib	Nilotinib
Antimalarial drugs	Quinine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ quinidine exposure • Inhibition of CYP 2D6 and Pgp by quinidine: ↑ imatinib exposure • Inhibition of hOCT1 by quinine : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ quinidine exposure • Inhibition of CYP 3A4 by dasatinib: ↑ quinidine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ quinidine exposure
	Chloroquine	<ul style="list-style-type: none"> • Inhibition of Pgp by chloroquine: ↑ imatinib exposure • Inhibition of hOCT1 by chloroquine : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by chloroquine: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
	Mefloquine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ mefloquine exposure • Inhibition of Pgp by mefloquine: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ mefloquine exposure • Inhibition of Pgp by mefloquine: ↑ dasatinib exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ mefloquine exposure • ↑ QT interval (additive effect) → monitor ECG
	Proguanil	<ul style="list-style-type: none"> • Inhibition of CYP 2C19 and Pgp by imatinib: ↑ proguanil exposure ↓ proguanil bioactivation 		
	Atovaquone			
	Doxycycline			

Immunomodulating agents **agentes inmunomoduladores**

		Imatinib	Dasatinib	Nilotinib
Immunosuppressants	Ciclosporin	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ ciclosporin exposure • Inhibition of Pgp and CYP 3A4 by ciclosporin: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ ciclosporin exposure • Inhibition of CYP3A4 and Pgp by ciclosporin: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ ciclosporin exposure • Inhibition of CYP3A4 by ciclosporin: ↑ nilotinib exposure
	Tacrolimus	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ tacrolimus exposure • Inhibition of Pgp by tacrolimus: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ tacrolimus exposure • Inhibition of Pgp by tacrolimus: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ tacrolimus exposure
	Sirolimus	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ sirolimus exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ sirolimus exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ sirolimus exposure
	Everolimus	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by imatinib: ↑ everolimus exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ everolimus exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by nilotinib: ↑ everolimus exposure
	Mycophenolate mofetil			
	Methotrexate			
	Azathioprine			

Musculo-skeletal system **Sistema músculo-esquelético**

		Imatinib	Dasatinib	Nilotinib
NSAIDs	Aspirin		<ul style="list-style-type: none"> • Thrombocytopenic effect of dasatinib: ↑ risk of bleeding 	
	Ibuprofen	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: ↑ ibuprofen exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 by dasatinib: ↑ ibuprofen exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 and 2C9 by nilotinib: ↑ ibuprofen exposure
	Mefenacid	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: ↑ mefenacid exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 by dasatinib: ↑ mefenacid exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 and 2C9 by nilotinib: ↑ mefenacid exposure
	Metamizole	<ul style="list-style-type: none"> • Induction of CYP 3A4 by metamizole: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by metamizole : ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by metamizole : ↓ nilotinib exposure
	Diclofenac	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by imatinib: ↑ diclofenac exposure • Inhibition of Pgp by diclofenac: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 by dasatinib: ↑ diclofenac exposure • Inhibition of Pgp by diclofenac: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C8 and 2C9 and by nilotinib: ↑ diclofenac exposure
Antigout preparations	Allopurinol			

Nervous system **sisistema nervioso**

		Imatinib	Dasatinib	Nilotinib
SSRI	Fluoxetine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ fluoxetine exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
	Fluvoxamine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ fluvoxamine exposure 		<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ fluvoxamine exposure
	Paroxetine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ paroxetine exposure 		<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ paroxetine exposure
	Citalopram	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ citalopram exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ citalopram exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib: ↑ citalopram exposure
	Sertraline	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ sertraline exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ sertraline exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib: ↑ sertraline exposure
SSNRI	Venlafaxine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ venlafaxine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ venlafaxine exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib: ↑ venlafaxine exposure • ↑ QT interval (additive effect) → monitor ECG
	Duloxetine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ duloxetine exposure 		<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ duloxetine exposure
Tetracyclic agent	Mirtazapine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ mirtazapine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ mirtazapine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib : ↑ mirtazapine exposure
Tricyclic agents	Trimipramine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ trimipramine exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG • Inhibition of CYP 2D6 by nilotinib: ↑ trimipramine exposure
	Amitriptyline	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ amitriptyline exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ amitriptyline exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib: ↑ amitriptyline exposure • ↑ QT interval (additive effect) → monitor ECG
Phenothiazines	Levomepromazine	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ levomepromazine exposure 		<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by nilotinib: ↑ levomepromazine exposure

		Imatinib	Dasatinib	Nilotinib
Z-drugs	Zolpidem	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ zolpidem exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ zolpidem exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ zolpidem exposure
	Zaleplon	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ zaleplon exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ zaleplon exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ zaleplon exposure
	Zopiclon	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ zopiclon exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ zopiclon exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ zopiclon exposure
Benzodiazepines	Alprazolam	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ alprazolam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ alprazolam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ alprazolam exposure
	Bromazepam	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ bromazepam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ bromazepam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ bromazepam exposure
	Clonazepam	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ clonazepam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ clonazepam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ clonazepam exposure
	Oxazepam			
	Lorazepam			
	Diazepam	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ diazepam exposure • Inhibition of CYP 3A4 by imatinib: ↑ midazolam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ diazepam exposure • Inhibition of CYP 3A4 by dasatinib: ↑ midazolam exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ diazepam exposure • Inhibition of CYP 3A4 by nilotinib: ↑ midazolam exposure
	Midazolam	<ul style="list-style-type: none"> • Inhibition of Pgp by midazolam: ↑ imatinib exposure • Inhibition of hOCT1 by midazolam : ↓ imatinib intracellular exposure 	<ul style="list-style-type: none"> • Inhibition of Pgp by midazolam: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ midazolam exposure
Barbiturates	Phenobarbital	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 2C19 by imatinib: ↑ phenobarbital exposure • Induction of CYP 3A4 by phenobarbital: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by phenobarbital: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: ↑ phenobarbital exposure • Induction of CYP 3A4 by phenobarbital: ↓ nilotinib exposure

		Imatinib	Dasatinib	Nilotinib
Antipsychotic agents	Haloperidol	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ haloperidol exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ haloperidol exposure • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
	Clozapine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib: ↑ clozapine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ clozapine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib: ↑ clozapine exposure
	Olanzapine			
	Risperidone	<ul style="list-style-type: none"> • Inhibition of CYP 2D6 by imatinib: ↑ risperidone exposure 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) → monitor ECG
Antiseizure drugs	Phenytoin	<ul style="list-style-type: none"> • Induction of CYP 3A4 by phenytoin : ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by phenytoin : ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by phenytoin : ↓ nilotinib exposure
	Valproic acid	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 and 2C19 by imatinib: ↑ valproic acid exposure • Inhibition of CYP 3A4 by valproic acid: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by valproic acid : ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 2C9 by nilotinib: ↑ valproic acid exposure • Inhibition of CYP 3A4 by valproic acid : ↑ nilotinib exposure
	Carbamazepine	<ul style="list-style-type: none"> • Induction of CYP 3A4 and Pgp by carbamazepine: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 and Pgp by carbamazepine: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by carbamazepine: ↓ nilotinib exposure
	Lamotrigine			
	Gabapentin			
	Topiramate	<ul style="list-style-type: none"> • Induction of CYP 3A4 by topiramate : ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by topiramate : ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by topiramate : ↓ nilotinib exposure
	Levetiracetam			
Antimaniac drug	Lithium			
Aminoketone	Bupropion			<ul style="list-style-type: none"> • Induction of CYP 2B6 by nilotinib: ↓ bupropion exposure ↑ bupropion bioactivation

		Imatinib	Dasatinib	Nilotinib
Opioids	Morphine			
	Tramadol	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib : ↑ tramadol exposure ↓ tramadol bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib : ↑ tramadol exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib : ↑ tramadol exposure ↓ tramadol bioactivation
	Methadone	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib : ↑ methadone exposure • Inhibition of Pgp by methadone: ↑ imatinib exposure. 	<ul style="list-style-type: none"> • ↑ QT interval (additive effect) • Inhibition of CYP 3A4 by dasatinib : ↑ methadone exposure • Inhibition of Pgp by methadone: ↑ dasatinib exposure. 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib : ↑ methadone exposure • Induction of CYP 2B6 by nilotinib: ↓ methadone exposure • ↑ QT interval (additive effect)
	Hydromorphone			
	Oxycodone	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by imatinib : ↑ oxycodone exposure ↓ oxycodone bioactivation 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib : ↑ oxycodone exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and 2D6 by nilotinib : ↑ oxycodone exposure ↓ oxycodone bioactivation
	Buprenorphine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib : ↑ buprenorphine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ buprenorphine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ buprenorphine exposure
Other	Acetaminophen	<ul style="list-style-type: none"> • Inhibition of o-glucuronidation by imatinib : ↑ acetaminophen exposure 		
Antimigraine preparations	Dihydroergotamine	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by imatinib: ↑ dihydroergotamine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by dasatinib: ↑ dihydroergotamine exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by nilotinib: ↑ dihydroergotamine exposure
	Sumatriptan			

Respiratory system **sistema respiratorio**

		Imatinib	Dasatinib	Nilotinib
H1-antagonists	Cetirizin			• Inhibition of Pgp by nilotinib: ↑ cetirizin exposure
	Levocetirizin			• Inhibition of Pgp by nilotinib: ↑ cetirizin exposure
	Loratadin	• Inhibition of CYP 3A4 by imatinib : ↑ loratadin exposure	• Inhibition of CYP 3A4 by dasatinib: ↑ loratadin exposure	• Inhibition of Pgp by nilotinib: ↑ loratadin exposure
	Fexofenadin			
Anti asthma drugs	Salbutamol			
	Theophylline			

Miscellaneous **diversos**

	Imatinib	Dasatinib	Nilotinib
St John's wort	<ul style="list-style-type: none"> • Induction of CYP 3A4 by St John's wort: ↓ imatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by St John's wort: ↓ dasatinib exposure 	<ul style="list-style-type: none"> • Induction of CYP 3A4 by St John's wort: ↓ nilotinib exposure
Grapefruit	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by grapefruit: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 and Pgp by grapefruit: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by grapefruit: ↑ nilotinib exposure
Licorice	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by licorice: ↑ imatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by licorice: ↑ dasatinib exposure 	<ul style="list-style-type: none"> • Inhibition of CYP 3A4 by licorice: ↑ nilotinib exposure

^a **TKIs en general pueden causar trombocitopenia, que suele ser de relevancia clínica, por favor tome esto en consideración cuando coadministre con medicación anticoagulante.**

ARTICULO COMPLETO EN INGLES EN LA SECCIÓN DE interacciones con otros medicamento DE ESTA WEB CON EL TITULO

Blood-2011-Haouala-e75-87 documento PDF